From theheart.org on Medscape

Coverage from the

American College of Cardiology 68th Annual Scientific Session (ACC) 2019

March 16 - 18, 2019; New Orleans, Louisiana

March 16 - 18, 2019 New Orleans, Louisiana

Booth #1911

Conference News

© WebMD, LLC

Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.

ACC 2019 on Twitter

Perspectives From ACC

 

Bloggers from the Floor

 
 

Popular News from ACC 2018

  • ODYSSEY: Alirocumab Cuts CV Events, All-Cause Death Post-ACS ODYSSEY: Alirocumab Cuts CV Events, All-Cause Death Post-ACS First evidence of survival benefit with PCSK9 inhibitor alirocumab reignites the call for greater access to these expensive drugs for patients not just with ACS but also with stable atherosclerotic CVD.
  • VEST: No Sudden Death Benefit Early Post-MI From LifeVest VEST: No Sudden Death Benefit Early Post-MI From LifeVest But defibrillators work by preventing sudden death, so it's a bit of a head-scratcher that all-cause mortality dropped instead for people who used the wearable defibrillator for 90 days after their MI.
  • Barbershop-Based Healthcare Cuts Hypertension in Blacks Barbershop-Based Healthcare Cuts Hypertension in Blacks An outreach program leveraging the community barbershop made impressive inroads combatting hypertension in black men, who have the highest hypertension-related death rate in the United States.

Previous Coverage